Stockreport
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi [Yahoo! Finance]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
The regulatory body has approved Leqembi as a treatment for adult patients with early AD who are apolipoprotein E e4 (ApoE e4) non-carriers or heterozygotes with confirmed amyloid pathology in Europe. Biogen's partner, Japan-based Eisai, leads the clinical development and regulatory submissions for Leqembi. Though both companies co-commercialize and co-promote the drug, Eisai has the final decision-making authority. Year to date, shares of Biogen have plunged 23.5% compared with the industry's decline of 6.5%. Image Source: Zacks Investment Research The approval for Leqembi in the EU is a positive for Biogen and Eisai, as it comes after several hurdles that delayed the approval timeline of the drug. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had given a negative opinion regarding the marketing approval of Leqembi for early AD in July 2024. Although patients given Leqembi had lower CDR-SB scores than those given placebo, the
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance][Yahoo! Finance]
- Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.[MarketBeat]
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Biogen (NASDAQ:BIIB) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.[MarketBeat]
- More
BIIB
SEC Filings
SEC Filings
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- BIIB's page on the SEC website
- More